(12) **Translation of European patent specification**

(11) **NO/EP 3233852 B1**

NORWAY

(19) NO

(51) Int Cl.

C07D 471/04 (2006.01)
A61K 31/437 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.09.21
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.07.15
(86)	European Application Nr.	15810660.9
(86)	European Filing Date	2015.12.17
(87)	The European Application's Publication Date	2017.10.25
(30)	Priority	2014.12.18, US, 201462093929 P 2015.02.02, US, 201562110998 P 2015.04.02, US, 201562142077 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Validation States:	MA
(73)	Proprietor	F. Hoffmann-La Roche AG, Grenzacherstrasse 124, 4070 Basel, Sveits
(72)	Inventor	GOODACRE, Simon Charles, c/o Argenta Discovery 2009 Limited8/9 Spire Green CentreFlex Meadow, HarlowEssex CM19 5TR, Storbritannia LABADIE, Sharada, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA LIANG, Jun, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA ORTWINE, Daniel Fred, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA RAY, Nicholas Charles, c/o Argenta Discovery 2009 Limited8/9 Spire Green CentreFlex Meadow, HarlowEssex CM19 5TR, Storbritannia WANG, Xiaojing, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA ZBIEG, Jason, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA ZHANG, Birong, c/o Genentech Inc.1 DNA Way, South San Francisco, California 94080, USA LAI, Kwong Wah, c/o WuXi AppTec (Shanghai) Co., Ltd.288 Fute Zuhong RoadWaigaoqiao Free Trade Zone, ShanghaiPRC 200131, Kina LIAO, Jiangpeng, c/o WuXi AppTec (Shanghai) Co., Ltd.288 Fute Zuhong RoadWaigaoqiao Free Trade Zone, ShanghaiPRC 200131, Kina LIU, Zhiguo, c/o WuXi AppTec (Shanghai) Co., Ltd.288 Fute Zuhong RoadWaigaoqiao Free Trade Zone, Shanghai PRC 200131, Kina WAI, John Sui-Man, c/o WuXi AppTec (Shanghai) Co., Ltd.288 Fute Zuhong RoadWaigaoqiao Free Trade Zone, ShanghaiPRC 200131, Kina

WANG, Tao, c/o WuXi AppTec (Shanghai) Co., Ltd.288 Fute Zuhong RoadWaigaoqiao Free Trade Zone, ShanghaiPRC 200131, Kina
LI, Jun, c/o Genentech, Inc.1 DNA Way, South San Francisco,CA 94080, USA

(74) Agent or Attorney PLOUGMANN VINGTOFT, Postboks 1003 Sentrum, 0104 OSLO, Norge

---

(54) Title **TETRAHYDRO-PYRIDO[3,4-B]INDOLES AS ESTROGEN RECEPTOR MODULATORS AND USES THEREOF**

(56) References Cited:
WO-A1-2008/127715
WO-A1-2013/090836
WO-A1-2010/138758
WO-A1-2010/138706
WO-A1-2010/138695

PATENTKRAV

1. Forbindelse valgt fra formel Ih:



Ih

eller stereoisomerer, tautomerer eller farmasøytisk akseptable salter derav, hvori:

Y^2 er $-(CH_2)$-;

R^a er valgt fra H, C_1-C_6-alkyl, C_2-C_8-alkenyl, propargyl, C_3-C_6-cykloalkyl og C_3-C_6-heterosyklyl, eventuelt substituert med én eller flere grupper uavhengig valgt fra F, Cl, Br, I, CN, OH, OCH_3 og SO_2CH_3;

R^b er uavhengig valgt fra H, $-O(C_1$-C_3-alkyl), C_1-C_6-alkyl, C_2-C_8-alkenyl, propargyl, $-(C_1$-C_6-alkyldiyl)-(C_3-C_6-cykloalkyl), C_3-C_6-cykloalkyl, og C_3-C_6-heterosyklyl, eventuelt substituert med én eller flere grupper uavhengig av hverandre valgt fraF, Cl, Br, I, CN, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2F$, OH, OCH_3 og SO_2CH_3;

R^c er valgt fra H, C_1-C_6-alkyl, allyl, propargyl, eventuelt substituert med én eller flere grupper uavhengig av hverandre valgt fra F, Cl, Br, I, CN, OH, OCH_3 og SO_2CH_3;

R^1, R^2, R^3 og R^4 er uavhengig av hverandre valgt fra H, F, Cl, Br, I, $-CN$, $-CH3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2OH$, CH_2OCH_3, $-CH_2CH_2OH$, $-C(CH_3)_2OH$, $-CH(OH)CH(CH_3)_2$, $-C(CH_3)_2CH_2OH$, $CH_2CH_2SO_2CH_3$, $-CH_2OP(O)(OH)_2$, $-CH_2F$, $-CHF_2$, $-CH_2NH_2$, $-CH_2NHSO_2CH_3$, $-CH_2NHCH_3$, $-CH_2N(CH_3)_2$, $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH(CH_3)CN$, $-C(CH_3)_2CN$, $-CH_2CN$, $-CO_2H$, $-COCH_3$, $-CO_2CH_3$, $-CO_2C(CH_3)_3$, $-COCH$ (OH) CH_3, $-CONH_2$, $-CONHCH_3$, $-CONHCH_2CH_3$, -$CONHCH(CH_3)_2$, $-CON(CH_3)_2$, $-C(CH_3)_2CONH_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, $-NHS(O)_2CH_3$, $-N(CH_3)C(CH_3)_2CONH_2$, $-N(CH_3)CH_2CH_2S(O)_2CH_3$, $-NO_2$, = O, $-OH$, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2OCH_3$, $-OCH_2CH_2OH$, $-OCH_2CH_2N$ $(CH_3)_2$, $-OP(O)(OH)_2$,

$-S(O)_2N(CH_3)_2$, $-SCH_3$, $-S(O)_2CH_3$, $-S(O)_3H$, cyklopropyl, cyklopropylamid, cyklobutyl, oksetanyl, azetidinyl, 1-metylazetidin-3-yl) oksy, N-metyl-N-oksetan-3-ylamino, azetidin-1-ylmetyl, benzyloksyfenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-metanon, piperazin-1-yl, morfolinometyl, morfolino-metanon og morfolino;

R^5 er valgt fra H, C_1-C_9-alkyl, C_3-C_9-cykloalkyl, C_3-C_9-heterosyklus, C_6-C_9-aryl, C_6-C_9-heteroaryl, $-(C_1$-C_6-alkyldiyl)-(C_3-C_9-cykloalkyl), $-(C_1$-C_6-alkyldiyl)-(C_3-C_9-heterosyklus), $C(O)R^b$, $C(O)NR^a$, SO_2R^a og SO_2NR^a, eventuelt substituert med ett eller flere halogen, CN, OR^a, $N(R^a)_2$, C_1-C_9-alkyl, C_3-C_9-cykloalkyl, C_3-C_9-heterosyklus, C_6-C_9-aryl, C_6-C_9-heteroaryl, $C(O)R^b$, $C(O)NR^a$, SO_2R^a og SO_2NR^a;

R^6 er valgt fra F, Cl, Br, I, $-CN$, $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2OH$, CH_2OCH_3, $-CH_2CH_2OH$, $-C(CH_3)_2OH$, $-CH(OH)CH(CH_3)_2$, $-C(CH_3)_2CH_2OH$, $CH_2CH_2SO_2CH_3$, $-CH_2OP(O)(OH)_2$, $-CH_2F$, $-CHF_2$, $-CH_2NH_2$, $-CH_2NHSO_2CH_3$, $-CH_2NHCH_3$, $-CH_2N(CH_3)_2$, $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2F$, $-CH(CH_3)CN$, $-C(CH_3)_2CN$, $-CH_2CN$, $-CO_2H$, $-COCH_3$, $-CO_2CH_3$, $-CO_2C(CH_3)_3$, $-COCH(OH)CH_3$, $-CONH_2$, -$CONHCH_3$, $-CONHCH_2CH_3$, $-CONHCH(CH_3)_2$, $-CON(CH_3)_2$, $-C(CH_3)_2CONH_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, $-NHS(O)_2CH_3$, $-N(CH_3)C(CH_3)_2CONH_2$, $-N(CH_3)CH_2CH_2S(O)_2CH_3$, $-NO_2$, = O, $-OH$, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2OCH_3$, $-OCH_2CH_2OH$, $-OCH_2CH_2N(CH_3)_2$, $-OP(O)(OH)_2$, $-S(O)_2N(CH_3)_2$, $-SCH_3$, $-S(O)_2CH_3$, $-S(O)_3H$, cyklopropyl, cyklopropylamid, cyklobutyl, oksetanyl, azetidinyl, 1-metylazetidin-3-yl) oksy, N-metyl-N-oksetan-3-ylamino, azetidin-1-ylmetyl, benzyloksyfenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-metanon, piperazin-1-yl, morfolinometyl, morfolino-metanon og morfolino;

R^7 er F, Cl, Br, I, $-CN$, $-CH_3$, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2OH$, CH_2OCH_3, $-CH_2CH_2OH$, $-C(CH_3)_2OH$, $-CH(OH)CH(CH_3)_2$, $-C(CH_3)_2CH_2OH$, $CH_2CH_2SO_2CH_3$, $-CH_2OP(O)(OH)_2$, $-CH_2F$, $-CHF_2$, $-CH_2NH_2$, $-CH_2NHSO_2CH_3$, $-CH_2NHCH_3$, $-CH_2N(CH_3)_2$, $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH(CH_3)CN$, $-C(CH_3)_2CN$, $-CH_2CN$, $-CO_2H$, $-COCH_3$, $-CO_2CH_3$, $-CO_2C(CH_3)_3$, $-COCH(OH)CH_3$, $-CONH_2$, $-CONHCH_3$, $-CONHCH_2CH_3$, -$CONHCH(CH_3)_2$, $-CON(CH_3)_2$, $-C(CH_3)_2CONH_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, $-NHS(O)_2CH_3$, $-N(CH_3)C(CH_3)_2CONH_2$, $-N(CH_3)CH_2CH_2S(O)_2CH_3$, $-NO_2$, = O, $-OH$, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2OCH_3$, $-OCH_2CH_2OH$,

$-OCH_2CH_2N(CH_3)_2$, $-OP(O)(OH)_2$, $-S(O)_2N(CH_3)_2$, $-SCH_3$, $-S(O)_2CH_3$, $-S(O)_3H$, cyklopropyl, cyklopropylamid, oksetanyl, azetidinyl, 1-metylazetidin-3-yl) oksy, N-metyl-N-oksetan-3-ylamino, azetidin-1-ylmetyl, benzyloksyfenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-metanon, piperazin-1-yl, morfolinometyl, morfolino-metanon og morfolino;

m er valgt fra 0, 1, 2, 3 og 4; og

n er valgt fra 0, 1, 2, 3 og 4;

hvor alkyldiyl, aryldiyl, carbocyklyldiyl, heterocyklyldiyl og heteroaryldiyl eventuelt er substituert med en eller flere grupper uavhengig av hverandre valgt fra F, Cl, Br, I, CCN, CH_3, $-CH_2CH_3$, $-CH(CH_3)_2$, $-CH_2CH(CH_3)_2$, $-CH_2OH$, CH_2OCH_3, $-CH_2CH_2OH$, $-C(CH_3)_2OH$, $-CH(OH)CH(CH_3)_2$, $-C(CH_3)_2CH_2OH$, $CH_2CH_2SO_2CH_3$, $-CH_2OP(O)(OH)_2$, $-CH_2F$, $-CHF_2$, $-CF_3$, $-CH_2CF_3$, $-CH_2CHF_2$, $-CH_2CH_2F$, $-CH(CH_3)CN$, $-C(CH_3)_2CN$, $-CH_2CN$, $-CH_2NH_2$, $-CH_2NHSO_2CH_3$, $-CH_2NHCH_3$, $-CH_2N(CH_3)_2$, $-CO_2H$, $-COCH_3$, $-CO_2CH_3$, $-CO_2C(CH_3)_3$, $-COCH(OH)CH_3$, $-CONH_2$, $-CONHCH_3$, $-CON(CH_3)_2$, $-C(CH_3)_2CONH_2$, $-NH_2$, $-NHCH_3$, $-N(CH_3)_2$, $-NHCOCH_3$, $-N(CH_3)COCH_3$, $-NHS(O)_2CH_3$, $-N(CH_3)C(CH_3)_2CONH_2$, $-N(CH_3)CH_2CH_2S(O)_2CH_3$, $-NO_2$, =O, $-OH$, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2OCH_3$, $-OCH_2CH_2OH$, $-OCH_2CH_2N(CH_3)_2$, $-OP(O)(OH)_2$, $-S(O)_2N(CH_3)_2$, $-SCH_3$, $-S(O)_2CH_3$, $-S(O)_3H$, cyklopropyl, cyklopropylamid, cyklobutyl, oksetanyl, azetidinyl, 1-metylazetidin-3-yl) oksy, N-metyl-N-oksetan-3-ylamino, azetidin-1-ylmetyl, benzyloksyfenyl, pyrrolidin-1-yl, pyrrolidin-1-yl-metanon, piperazin-1-yl, morfolinometyl, morfolino-metanon og morfolino.

2. Forbindelsen ifølge krav 1, hvori R^c er H.

3. Forbindelsen ifølge krav 1, hvori R^1 og R^2 er H.

4. Forbindelsen ifølge krav 1, hvori R^3 er H, og R^4 er $-CH_3$.

5. Forbindelsen ifølge krav 1, hvori R^5 er C_1-C_6-fluoralkyl.

6. Forbindelsen ifølge krav 1, hvori m er 0.

7. Forbindelsen ifølge krav 1 valgt fra:

N-(3,5-difluor-4-((1R,3R)-2-(2-fluor-2-metylpropyl)-3-metyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
(R)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-

metylpropan-1-ol;
(S)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-metylpropan-1-ol;
(R)-2-fluor-3-((1R,3R)-1-(2-fluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropan-1-ol;
(S)-2-fluor-3-((1R,3R)-1-(2-fluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropan-1-ol;
(R)-2-fluor-3-((1R,3R)-1-(4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropan-1-ol;
(S)-2-fluor-3-((1R,3R)-1-(4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-metylpropan-1-ol;
N-(3,5-difluor-4-((1R,3R)-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
1-(3-fluorpropyl)-N-[4-[(1R,3R)-3-metyl-2-metylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]fenyl]azetidin-3-amin;
N-[3,5-difluor-4-[(1R,3R)-3-metyl-2-metylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]fenyl]-1-(3-fluorpropyl)azetidin-3-amin;
1-(3-fluorpropyl)-N-[4-[(1S,3R)-3-metyl-2-metylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]fenyl]azetidin-3-amin;
N-[3,5-difluor-4-[(1S,3R)-3-metyl-2-metylsulfonyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]fenyl]-1-(3-fluorpropyl)azetidin-3-amin;
3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluor-propan-1-ol;
(2R)-3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-metyl-propansyre;
3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluorpropan-1-ol;
3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-

difluorpropan-1-ol;
(2S)-3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2-metyl-propansyre;
N-(3,5-difluor-4-((1R,3R)-6-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1S,3S)-6-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-dimetylpropansyre;
N-(3,5-difluor-4-((1R,3R)-6-fluor-3-metyl-2-(metylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1S,3S)-6-fluor-3-metyl-2-(metylsulfonyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(4-((1R,3R)-2-(2,2-difluoretyl)-6-fluor-3-metyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorfenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(4-((1S,3S)-2-(2,2-difluoretyl)-6-fluor-3-metyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorfenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1R,3R)-7-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1S,3S)-7-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
(S)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(R)-3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(R)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(S)-3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;

N-(3,5-difluor-4-((1R,3R)-2-(2-fluor-2-metylpropyl)-3-metyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)-N-metylazetidin-3-amin;
(R)-N-(4-(2-(2,2-difluoretyl)-3,3-dimetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorfenyl)-1-(3-fluorpropyl)azetidin-3-amin;
(S)-N-(4-(2-(2,2-difluoretyl)-3,3-dimetyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)-3,5-difluorfenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1R,3R)-5-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1S,3S)-5-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1S,3S)-8-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
N-(3,5-difluor-4-((1R,3R)-8-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin;
(S)-3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(R)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(S)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
(R)-3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-metylpropan-1-ol;
3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-5-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
(R)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-

3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-(hydroksymetyl)propannitril;
(S)3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2-fluor-2-(hydroksymetyl)propannitril;
(R)-3-(1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3,3-dimetyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
(S)-3-(1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-3,3-dimetyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-8-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-8-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-7-fluor-3-metyl-3,4-dihydro-1H-pyrido[3,4-b]indol-2(9H)-yl)-2,2-difluorpropan-1-ol;
N-[4-[(1R,3R)-2-(2,2-difluoretyl)-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]-3,5-difluor-fenyl]-1-(3-fluorpropyl)azetidin-3-amin;
(R)-3-((2R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-metylpropan-1-ol;
(S)-3-((1S,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-metylpropan-1-ol;
(S)-3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-metylpropan-1-ol;
(R)-3-((1R,3S)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2-fluor-2-

metylpropan-1-ol;

8. Forbindelsen av formel Ih ifølge krav 1, eller farmasøytisk akseptable salter derav, hvori forbindelsen av formel Ih er 3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluor-propan-1-ol eller et farmasøytisk akseptabelt salt derav.



9. Forbindelsen av formel Ih ifølge krav 1, hvori forbindelsen av formel Ih er 3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluor-propan-1-ol.



10. Farmasøytisk akseptabelt salt av forbindelsen av formel Ih ifølge krav 1, hvori forbindelsen av formel Ih er 3-[(1R,3R)-1-[2,6-difluor-4-[[1-(3-fluorpropyl)azetidin-3-yl]amino]fenyl]-3-metyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]-2,2-difluor-propan-1-ol.



11. Forbindelsen av formel Ih ifølge krav 1, eller farmasøytisk akseptable salter derav, hvori forbindelsen av formel Ih er 3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluorpropan-1-ol eller et farmasøytisk akseptabelt salt derav.



12. Forbindelsen av formel Ih ifølge krav 1, hvori forbindelsen av formel Ih er 3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluorpropan-1-ol.



13. Farmasøytisk akseptabelt salt av forbindelsen av formel Ih ifølge krav 1, hvori forbindelsen av formel Ih er 3-((1R,3R)-1-(2,6-difluor-4-((1-(3-fluorpropyl)azetidin-3-yl)amino)fenyl)-6-fluor-3-metyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluorpropan-1-ol.



14. Forbindelsen av formel Ih ifølge krav 1, eller farmasøytisk akseptable salter derav, hvori forbindelsen av formel Ih er *N*-(3,5-difluor-4-((1*R*,3*R*)-7-fluor-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1*H*-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin eller et farmasøytisk akseptabelt salt derav.



15. Forbindelsen av formel Ih ifølge krav 1, eller farmasøytisk akseptable salter derav, hvori forbindelsen av formel Ih er N-(3,5-difluor-4-((1R,3R)-3-metyl-2-(2,2,2-trifluoretyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)fenyl)-1-(3-fluorpropyl)azetidin-3-amin eller et farmasøytisk akseptabelt salt derav.



16. Farmasøytisk sammensetning som omfatter en forbindelse ifølge et hvilket som helst av kravene 1 til 15 og en farmasøytisk akseptabel eksipiens.

17. Forbindelse ifølge et hvilket som helst av kravene 1 til 15 for anvendelse som terapeutisk aktivt stoff.

18. Forbindelse ifølge et hvilket som helst av kravene 1 til 15 for anvendelse i behandling av en ER-relatert sykdom eller lidelse, hvori den ER-relaterte sykdommen eller lidelsen er kreft valgt fra brystkreft, lungekreft, kreft i eggstokkene, livmorslimhinnekreft, prostatakreft og livmorkreft.
19. Forbindelsen for anvendelse ifølge krav 18, hvori kreften er brystkreft.
20. Forbindelsen for anvendelse ifølge krav 19, hvori brystkreften er hormonreseptorpositiv metastatisk brystkreft.
21. Forbindelsen for anvendelse ifølge krav 19, hvori brystkreften er hormonavhengig brystkreft.
22. Forbindelsen for anvendelse ifølge krav 19, hvori brystkreften er en østrogenreseptoravhengig brystkreft.
23. Forbindelsen for anvendelse ifølge krav 19, hvori brystkreften er en hormonrefraktær brystkreft.
24. Forbindelsen for anvendelse ifølge et hvilket som helst av kravene 19 til 23, hvori kreften er resistent mot anti-hormonell behandling.
25. Forbindelsen for anvendelse ifølge krav 24, hvori den anti-hormonelle behandlingen omfatter tamoksifen, fulvestrant, steroide aromataseinhibitorer eller ikke-steroide aromataseinhibitorer.
26. Forbindelsen for anvendelse ifølge krav 19, hvori brystkreften aldri er blitt behandlet med cellegift.
27. Forbindelsen for anvendelse ifølge et hvilket som helst av kravene 19 til 26, hvori forbindelsen administreres i kombinasjon med en CDK4/6-inhibitor.
28. Forbindelsen for anvendelse ifølge krav 27, hvori CDK4/6-inhibitoren er palbociclib, ribociclib eller LY283519.